Unknown

Dataset Information

0

Preserved C-reactive protein responses to blood stream infections following tocilizumab treatment for COVID-19.

ABSTRACT:

SUBMITTER: Wey EQ 

PROVIDER: S-EPMC8363426 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Bowel ulceration following tocilizumab administration in a COVID-19 patient.
| S-EPMC7437943 | biostudies-literature
Transcriptomics Pre-existing cross-reactive antibody responses do not significantly impact inactivated COVID-19 vaccine-induced neutralization
2021-10-13 | E-MTAB-11084 | biostudies-arrayexpress
Transcriptomics Pre-existing cross-reactive antibody responses do not significantly impact inactivated COVID-19 vaccine-induced neutralization
2021-10-29 | E-MTAB-11117 | biostudies-arrayexpress
Unknown Proteomic blood profiling in mild, severe and critical COVID-19 patients
| S-BSST416 | biostudies-other
Unknown Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients.
| S-EPMC8340482 | biostudies-literature
Unknown Thromboinflammation response to tocilizumab in COVID-19.
| S-EPMC7537313 | biostudies-literature
Transcriptomics Single Cell RNAseq and VDJ sequence of ACE2 reactive and non-reactive B-cells isolated from COVID-19 patients peripheral blood
2023-06-01 | GSE178123 | GEO
Unknown Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.
| S-EPMC7781101 | biostudies-literature
Unknown Tocilizumab in COVID-19: The Cerrahpasa-PREDICT score.
| S-EPMC8114762 | biostudies-literature
Unknown Repurposed Tocilizumab in Patients with Severe COVID-19.
| S-EPMC7812057 | biostudies-literature